[go: up one dir, main page]

WO2011096698A3 - Composition for cancer prognosis prediction comprising anti-tmap/ckap2 antibodies - Google Patents

Composition for cancer prognosis prediction comprising anti-tmap/ckap2 antibodies Download PDF

Info

Publication number
WO2011096698A3
WO2011096698A3 PCT/KR2011/000691 KR2011000691W WO2011096698A3 WO 2011096698 A3 WO2011096698 A3 WO 2011096698A3 KR 2011000691 W KR2011000691 W KR 2011000691W WO 2011096698 A3 WO2011096698 A3 WO 2011096698A3
Authority
WO
WIPO (PCT)
Prior art keywords
tmap
ckap2
composition
cancer prognosis
prognosis prediction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/000691
Other languages
French (fr)
Korean (ko)
Other versions
WO2011096698A2 (en
WO2011096698A9 (en
Inventor
신창호
홍경만
배창대
박주배
최용복
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
National Cancer Center Korea
Sungkyunkwan University Foundation for Corporate Collaboration
Original Assignee
National Cancer Center Japan
National Cancer Center Korea
Sungkyunkwan University Foundation for Corporate Collaboration
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100081081A external-priority patent/KR20110091423A/en
Application filed by National Cancer Center Japan, National Cancer Center Korea, Sungkyunkwan University Foundation for Corporate Collaboration filed Critical National Cancer Center Japan
Priority to US13/577,126 priority Critical patent/US8980570B2/en
Publication of WO2011096698A2 publication Critical patent/WO2011096698A2/en
Publication of WO2011096698A3 publication Critical patent/WO2011096698A3/en
Publication of WO2011096698A9 publication Critical patent/WO2011096698A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to an antibody which specifically binds to TMAP (tumour associated microtubule associated protein)/CKAP2 (cytoskeleton associated protein 2) or a fragment of the same, and to a method for confirming the presence or absence of mitosis and a method for predicting cancer prognosis by using the same. More specifically, the present invention relates to a composition for cancer prognosis prediction comprising anti-TMAP/CKAP2 antibodies or an antigen-binding site thereof, a method for detecting TMAP/CKAP2 by using the composition, an anti-TMAP/CKAP2 antibody for cancer prognosis prediction, a method for providing information for cancer prognosis prediction using the composition, a cancer-treatment agent screening method comprising the measurement of changes in the level of TMAP/CKAP2 antigen-antibody reaction by the treatment of a candidate substance, and a composition for measuring cell-division cycles using the composition.
PCT/KR2011/000691 2010-02-05 2011-02-01 Composition for cancer prognosis prediction comprising anti-tmap/ckap2 antibodies Ceased WO2011096698A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/577,126 US8980570B2 (en) 2010-02-05 2011-02-01 Composition for cancer prognosis prediction comprising anti-TMAP/CKAP2 antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0011126 2010-02-05
KR20100011126 2010-02-05
KR10-2010-0081081 2010-08-20
KR1020100081081A KR20110091423A (en) 2010-02-05 2010-08-20 Composition for diagnosing prognosis of cancer containing anti-TPM / CPAAP2 antibody

Publications (3)

Publication Number Publication Date
WO2011096698A2 WO2011096698A2 (en) 2011-08-11
WO2011096698A3 true WO2011096698A3 (en) 2011-12-29
WO2011096698A9 WO2011096698A9 (en) 2012-03-01

Family

ID=44355942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000691 Ceased WO2011096698A2 (en) 2010-02-05 2011-02-01 Composition for cancer prognosis prediction comprising anti-tmap/ckap2 antibodies

Country Status (1)

Country Link
WO (1) WO2011096698A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093794A2 (en) * 2002-05-01 2003-11-13 Irm Llc Methods for discovering tumor biomarkers and diagnosing tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093794A2 (en) * 2002-05-01 2003-11-13 Irm Llc Methods for discovering tumor biomarkers and diagnosing tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONG KU ET AL.: "Cdkl-Cyclin B1-mediated Phosphorylation of Tumor-associated Microtubule-associated Protein/Cytoskeleton-associated Protein 2 in Mitosis.", J. BIOLOGICAL CHEMISTRY, vol. 284, no. 24, 2009, pages 16501 - 16512 *
HONG KU ET AL.: "Transient phosphorylation of tumor associated microtubule associated protein (TMAP)/cytoskeleton associated protein 2 (CKAP2) at Thr-596 during early phases of mitosis.", EXPERIMENTAL AND MOLECULAR MEDICINE., vol. 4, no. 4, 2008, pages 377 - 386 *

Also Published As

Publication number Publication date
WO2011096698A2 (en) 2011-08-11
WO2011096698A9 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
MX2014001377A (en) Method for detecting pancreatic cancer.
MX361502B (en) Antibodies that bind to human programmed death ligand 1 (pd-l1).
MacNeil et al. Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry
IN2013CN01129A (en)
BRPI0906903B8 (en) monoclonal antibody and cd70 expression detection method
JP2015533788A5 (en)
MX2009004460A (en) Immunoassay of analytes in samples containing endogenous anti-analyte antibodies.
JP2017518366A5 (en)
HK1219763A1 (en) Compositions and methods for cancer prognosis
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
Chen et al. Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion
WO2015038884A3 (en) Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
WO2012075506A3 (en) Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
WO2008101177A3 (en) Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
MX2019006098A (en) Antibody assay.
WO2012112013A3 (en) A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer
WO2012050365A3 (en) Biomarker for diagnosing glioblastoma or predicting prognosis of glioblastoma patients, and use thereof
WO2009121024A3 (en) Methods for detecting antibodies
WO2019074333A3 (en) Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto
Goto et al. Quantitative LC-MS/MS analysis of proteins involved in metastasis of breast cancer
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2012174569A3 (en) New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
DK2024748T3 (en) Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11739994

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13577126

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11739994

Country of ref document: EP

Kind code of ref document: A2